Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.
Predictive Oncology Inc. (NASDAQ: POAI) is at the forefront of using data and artificial intelligence (AI) to create personalized cancer treatments, aiming for more effective therapies and better patient outcomes. The company's mission revolves around precision medicine in cancer diagnosis, leveraging several key resources:
- Database: A comprehensive database of clinically validated historical and outcome data from patient tumors.
- CLIA-Certified Lab: An in-house Clinical Laboratory Improvement Amendments (CLIA) certified lab.
- Smart Tumor Profiling: A patient-derived tumor profiling platform that offers intelligent insights.
- Bioinformatics AI Platform: An advanced AI platform for in-house bioinformatics.
- Innovative Tumor Growth: Techniques for growing tumors in the lab to rapidly develop patient-specific treatment options.
- FDA-Approved System: The FDA-approved STREAMWAY System for automated medical fluid waste management.
Predictive Oncology's business is structured across three main segments:
- Pittsburgh Segment: Focuses on AI applications using a proprietary biobank with over 150,000 tumor samples and creates 3D culture models for drug development.
- Birmingham Segment: Provides contract research services targeting solubility improvements, stability studies, and protein production.
- Eagan Segment: Produces the FDA-cleared STREAMWAY System for medical fluid disposal, driving the majority of the company's revenue.
Recent achievements highlight the company's collaborative efforts with pharmaceutical, diagnostic, and biotech industries:
- Hosted an investor call and webcast on November 14th, providing insights into future strategies and financial performance.
- Presented a study in collaboration with UPMC Magee-Womens Hospital, utilizing AI to predict ovarian cancer survival outcomes better than clinical data alone.
- Announced a partnership with FluGen to develop a stable intranasal flu vaccine, leveraging Predictive Oncology’s biologics capabilities.
- Unveiled a proprietary 3D cell culture model to enhance cancer drug discovery.
- Introduced a new platform for functional and stable G-Protein Coupled Receptors (GPCRs), targeting advancements in cancer therapeutics.
Predictive Oncology's AI platform, PEDAL, has been validated to predict tumor sample responses to drug compounds with 92% accuracy. This platform, combined with the company's biobank of over 150,000 tumor samples and CLIA lab facilities, positions Predictive Oncology as a leader in AI-driven drug discovery and development.
Predictive Oncology (NASDAQ: POAI) declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock for each common share held as of March 27, 2023. The Series F Preferred Stock will confer significant voting rights, including 1,000,000 votes per share on issues related to a proposed reverse stock split. Any shares not voted will be automatically redeemed. The Preferred Stock is uncertificated and non-transferable, except with the transfer of common stock. Further details will follow in a Form 8-K report. This action aims to facilitate the company's corporate governance and potential structural changes.
Predictive Oncology (Nasdaq: POAI) has engaged LifeSci Advisors to implement a comprehensive investor relations program aimed at raising awareness of its proprietary drug discovery assets. CEO Raymond F. Vennare emphasized the company's potential, leveraging its artificial intelligence drug discovery engine, PEDAL™, alongside a biobank of over 150,000 tumor samples. With the AI-assisted drug development market valued at $1.1 billion and growing at 30% annually, the timing is opportune for outreach to analysts and institutional investors.
Predictive Oncology (Nasdaq: POAI) announced significant progress in drug discovery and development, focusing on leveraging its AI-driven PEDAL platform and substantial biobank of tumor samples. The company aims to revitalize cancer therapy development through strategic partnerships, like the recent collaboration with Cvergenx, and a new initiative, Accelerating Compound Exploration (ACE). The company holds a strong cash position for at least 18 months, with plans to address Nasdaq listing requirements due to a price deficiency. The rapidly growing AI drug discovery market presents opportunities, as Predictive’s innovative solutions position it favorably against industry challenges.
Predictive Oncology Inc. (NASDAQ: POAI) announced a strategic partnership with Cvergenx on February 23, 2023, aimed at transforming radiation oncology through a genomics-based AI approach. This collaboration will utilize Predictive Oncology’s drug discovery and AI capabilities alongside Cvergenx’s precision genomics radiation therapy platform (pGRT™) to optimize radiotherapy for better patient outcomes. The partnership seeks to tailor radiation doses based on individual tumor biology, potentially saving an estimated 40,000 lives annually if overall patient survival improves by just 4%.
CEO Raymond Vennare emphasizes that this innovation could shift radiation therapy into the era of precision medicine.
Predictive Oncology Inc. (NASDAQ: POAI) launched the ACE (Accelerating Compound Exploration) program, aimed at enhancing oncology drug development with academic institutions. This initiative will provide early-stage researchers access to the company's PEDAL platform, which utilizes machine learning and a biobank of 150K tumor samples to evaluate drug compounds. The ACE program seeks to expedite the identification of promising drug candidates while alleviating funding constraints. No up-front costs will be incurred by participating investigators. Applications are accepted until March 31, 2023.
Predictive Oncology (NASDAQ: POAI) has appointed Pamela Bush, Ph.D., MBA, as the new Chief Business Officer. Dr. Bush will oversee business development and growth strategies, enhancing oncology drug discovery efforts in collaboration with biopharma partners. With over 20 years of experience, including her previous role as Senior Vice President at Predictive Oncology, she aims to lead strategic and operational initiatives to expedite drug development processes. CEO Raymond F. Vennare praised her extensive industry expertise and insights. Dr. Bush's leadership is expected to significantly impact the company’s direction and operational growth.
Predictive Oncology (NASDAQ: POAI) appointed Dr. Robert F. Murphy to its Scientific Advisory Board, enhancing its research capabilities. Dr. Murphy, a pioneer in machine learning for biological data, previously led the Computational Biology Department at Carnegie Mellon University. His expertise will support the company's goal of advancing cancer therapies through its PEDAL platform, which integrates machine learning with a biobank of over 150,000 tumor samples. The move is expected to strengthen Predictive Oncology's scientific initiatives and growth strategy.
Predictive Oncology (NASDAQ: POAI) has appointed Dr. Marc Malandro to its Scientific Advisory Board, enhancing its leadership amidst its focus on cancer research and drug development. Dr. Malandro, Vice President at the Chan Zuckerberg Initiative, brings extensive expertise in genomics and biopharmaceuticals. His appointment aims to bolster partnerships with pharmaceutical companies and accelerate the company's drug discovery initiatives. Predictive Oncology leverages AI and a biobank of over 150,000 cancer tumors to improve oncological therapies and patient outcomes.
Predictive Oncology (NASDAQ: POAI) has appointed Matthew J. Hawryluk, Ph.D., to its Board of Directors to bolster strategic initiatives and commercialization efforts. Dr. Hawryluk, currently the Executive Vice President and Chief Business Officer of Gritstone bio, is recognized for his expertise in the biopharma industry and has been instrumental in achieving over 20 FDA approvals. His background includes roles at Foundation Medicine and Thermo Fisher Scientific. This appointment aims to enhance Predictive Oncology's capacity in AI-driven cancer therapy development.
Predictive Oncology (NASDAQ: POAI) reported a 45% revenue growth for Q3 2022, totaling $455,827, compared to $313,663 in Q3 2021, along with an improved gross profit margin of 76%, up from 65% year-over-year. The company appointed Raymond F. Vennare as CEO and Chairman, signaling a leadership shift. Operating cash flow increased by 8% year-over-year, but net loss for the first nine months of 2022 grew to $17,821,524 due to a substantial goodwill impairment. The company ended the quarter with $25,393,738 in cash.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
What does Predictive Oncology Inc. specialize in?
What are the key segments of Predictive Oncology’s business?
What recent collaborations has Predictive Oncology announced?
How accurate is Predictive Oncology’s AI platform PEDAL?
What is the significance of Predictive Oncology’s 3D cell culture model?
How does Predictive Oncology’s STREAMWAY System benefit the healthcare industry?
What are GPCRs and why are they important in cancer treatment?
What is Predictive Oncology’s biobank?
Where is Predictive Oncology headquartered?
Who can I contact for investor relations at Predictive Oncology?
